Making medicines essential: The emergent centrality of pharmaceuticals in global health

Research output: Contribution to journalArticle

Abstract

Expanding access to pharmaceuticals has become one of the most visible aspects of twenty-first century global health practices, as evidenced by the moral urgency of antiretroviral rollout and the pressing call for new drugs for neglected diseases. However, the role of prescription drugs in public health was far less obvious to the framers of international health organizations only a half-century ago. This article examines the evolving role of pharmaceuticals in global health practices by charting the emergence of the category of essential medicines: initially a list of 186 drugs first defined by the World Health Organization (WHO) in 1977 to be basic, indispensable, and necessary for the health of the population, and subsequently expanded by actors beyond the WHO including NGOs, pharmaceutical companies and the broader financial community. This apparently simple act of list-making worked to transport a set of commodities from the private, commercial sphere into a public health commons, and sparked a series of methodological, logistical and political controversies over the winnowing of essential from inessential that collapsed evidentiary, regulatory, participatory and market terms into a single process. To ask what practices render a medicine essential? is therefore to address the shifting ecology of knowledge governing global health today.

Original languageEnglish (US)
Pages (from-to)10-33
Number of pages24
JournalBioSocieties
Volume6
Issue number1
DOIs
StatePublished - Mar 2011
Externally publishedYes

Fingerprint

pharmaceutical
medicine
health
Pharmaceutical Preparations
drug
WHO
Public Health
public health
Neglected Diseases
Prescription Drugs
Health
Ecology
twenty-first century
non-governmental organization
commodity
ecology
medication
Medicine
Global Health
Organizations

Keywords

  • essential drugs
  • essential medicines
  • global health
  • global pharmaceuticals
  • international health
  • pharmaceutical industry

ASJC Scopus subject areas

  • Health Policy
  • Health(social science)

Cite this

Making medicines essential : The emergent centrality of pharmaceuticals in global health. / Greene, Jeremy.

In: BioSocieties, Vol. 6, No. 1, 03.2011, p. 10-33.

Research output: Contribution to journalArticle

@article{899e2309300f4d2f9e7a73e81156ad23,
title = "Making medicines essential: The emergent centrality of pharmaceuticals in global health",
abstract = "Expanding access to pharmaceuticals has become one of the most visible aspects of twenty-first century global health practices, as evidenced by the moral urgency of antiretroviral rollout and the pressing call for new drugs for neglected diseases. However, the role of prescription drugs in public health was far less obvious to the framers of international health organizations only a half-century ago. This article examines the evolving role of pharmaceuticals in global health practices by charting the emergence of the category of essential medicines: initially a list of 186 drugs first defined by the World Health Organization (WHO) in 1977 to be basic, indispensable, and necessary for the health of the population, and subsequently expanded by actors beyond the WHO including NGOs, pharmaceutical companies and the broader financial community. This apparently simple act of list-making worked to transport a set of commodities from the private, commercial sphere into a public health commons, and sparked a series of methodological, logistical and political controversies over the winnowing of essential from inessential that collapsed evidentiary, regulatory, participatory and market terms into a single process. To ask what practices render a medicine essential? is therefore to address the shifting ecology of knowledge governing global health today.",
keywords = "essential drugs, essential medicines, global health, global pharmaceuticals, international health, pharmaceutical industry",
author = "Jeremy Greene",
year = "2011",
month = "3",
doi = "10.1057/biosoc.2010.39",
language = "English (US)",
volume = "6",
pages = "10--33",
journal = "BioSocieties",
issn = "1745-8552",
publisher = "Palgrave Macmillan Ltd.",
number = "1",

}

TY - JOUR

T1 - Making medicines essential

T2 - The emergent centrality of pharmaceuticals in global health

AU - Greene, Jeremy

PY - 2011/3

Y1 - 2011/3

N2 - Expanding access to pharmaceuticals has become one of the most visible aspects of twenty-first century global health practices, as evidenced by the moral urgency of antiretroviral rollout and the pressing call for new drugs for neglected diseases. However, the role of prescription drugs in public health was far less obvious to the framers of international health organizations only a half-century ago. This article examines the evolving role of pharmaceuticals in global health practices by charting the emergence of the category of essential medicines: initially a list of 186 drugs first defined by the World Health Organization (WHO) in 1977 to be basic, indispensable, and necessary for the health of the population, and subsequently expanded by actors beyond the WHO including NGOs, pharmaceutical companies and the broader financial community. This apparently simple act of list-making worked to transport a set of commodities from the private, commercial sphere into a public health commons, and sparked a series of methodological, logistical and political controversies over the winnowing of essential from inessential that collapsed evidentiary, regulatory, participatory and market terms into a single process. To ask what practices render a medicine essential? is therefore to address the shifting ecology of knowledge governing global health today.

AB - Expanding access to pharmaceuticals has become one of the most visible aspects of twenty-first century global health practices, as evidenced by the moral urgency of antiretroviral rollout and the pressing call for new drugs for neglected diseases. However, the role of prescription drugs in public health was far less obvious to the framers of international health organizations only a half-century ago. This article examines the evolving role of pharmaceuticals in global health practices by charting the emergence of the category of essential medicines: initially a list of 186 drugs first defined by the World Health Organization (WHO) in 1977 to be basic, indispensable, and necessary for the health of the population, and subsequently expanded by actors beyond the WHO including NGOs, pharmaceutical companies and the broader financial community. This apparently simple act of list-making worked to transport a set of commodities from the private, commercial sphere into a public health commons, and sparked a series of methodological, logistical and political controversies over the winnowing of essential from inessential that collapsed evidentiary, regulatory, participatory and market terms into a single process. To ask what practices render a medicine essential? is therefore to address the shifting ecology of knowledge governing global health today.

KW - essential drugs

KW - essential medicines

KW - global health

KW - global pharmaceuticals

KW - international health

KW - pharmaceutical industry

UR - http://www.scopus.com/inward/record.url?scp=84860389661&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84860389661&partnerID=8YFLogxK

U2 - 10.1057/biosoc.2010.39

DO - 10.1057/biosoc.2010.39

M3 - Article

AN - SCOPUS:84860389661

VL - 6

SP - 10

EP - 33

JO - BioSocieties

JF - BioSocieties

SN - 1745-8552

IS - 1

ER -